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Abstract
Congenital adrenal hyperplasia associated with deficiency of steroid
21-hydroxylase is the most common inborn error in adrenal function and the
most common cause of adrenal insufficiency in the pediatric age group. As
patients now survive into adulthood, adult health-care providers must also be
familiar with this condition. Over the past several years, F1000 has published
numerous commentaries updating research and practical guidelines for this
condition. The purposes of this review are to summarize basic information
defining congenital adrenal hyperplasia and to highlight current knowledge and
controversies in management.
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Introduction
In most patients with classic congenital adrenal hyperplasia (CAH),
both cortisol and aldosterone production are impaired while adrenal androgen production is excessive. As a result of the lack of the
vital hormones cortisol and aldosterone, patients are susceptible to
potentially lethal adrenal insufficiency if untreated. Thus, emergency and critical care personnel must consider the diagnosis in
patients presenting in shock. Excess androgen production, a side
effect of 21-hydroxylase deficiency, causes genital ambiguity in
females along with various endocrinologic, gynecologic, and reproductive complications. Men with CAH may also have reproductive
and endocrine problems, most notably testicular adrenal rest tumors
and oligospermia.
In this context, I will present data and arguments supporting the
need for informed treatment of patients across the life span and
across primary and specialty care practices. The main themes to
be discussed will be prenatal and neonatal diagnosis, optimization
of growth during childhood, and quality of life (QOL), including
reproductive health in adult life.

Prenatal and neonatal diagnosis
CAH is a monogenic autosomal recessive disease caused by
mutations or deletions in CYP21A2, the gene encoding steroid
21-hydroxylase1,2. All newborns in the United States and in many
developed countries are screened for 21-hydroxylase deficiency
among other disorders diagnosed by obtaining heel-stick blood
on filter paper3. At present, the diagnosis is most often made by
immunoassays for 17-hydroxyprogesterone. The assay methods
have changed over time in an effort to improve the rather poor
positive predictive value of these tests. Innovations in this regard
have included stratifying cut-points by birth weight, introducing
ratios of various analytes, and using the more specific methods of
tandem mass spectrometry. In some screening programs, a second
blood sample is obtained after several weeks to capture potentially
missed cases. It is believed that newborn screening has significantly
improved infant morbidity and mortality because of earlier diagnosis and treatment of these babies at risk for sudden death due to
adrenal insufficiency4. It has further been estimated that the costbenefit ratio for screening is comparable to that of other inborn
errors of metabolism for which screening has been mandated4,5.
Genotyping for screening purposes so far has not been deemed
cost-effective. Rather, genotyping is most often performed when
the hormonal diagnosis is in question or when genetic counseling
is indicated6. A common scenario is that the family with a proband
affected with CAH is seeking prenatal diagnosis for a fetus. If one
knows the proband’s genotype, fetal diagnosis can be accomplished
during the first trimester by several approaches. Whereas in the past
chorionic sampling was performed at about 10 weeks’ gestation,
the novel approach of extracting fetal DNA from the maternal circulation at as early as 5 to 6 weeks holds promise for earlier anticipatory guidance7. Another reproductive option for couples at risk
for this and other well-characterized monogenic disorders is preimplantation genetic screening to avoid producing a second affected
child, although this procedure is considered by some to be eugenic
and is quite expensive and still not widely available8.

Prenatal treatment of the fetus via dexamethasone administration
to the pregnant mother is potentially fraught with unknown longterm risks based on both human and animal studies9. The Endocrine Society and other medical groups have deemed this practice
experimental6. Swedish investigators have placed a moratorium on
the practice10.

Optimization of growth during childhood
The primary goal of treating classic CAH is to reduce the excess
adrenal androgen production and replace the deficient hormones,
namely cortisol and aldosterone. Proper treatment will prevent both
adrenal crisis and ongoing virilization. Daily oral medications,
including glucocorticoids, mineralocorticoids, and salt supplements, are prescribed at the time of diagnosis in infancy and titrated
according to blood levels of adrenal steroids, plasma renin activity,
and electrolytes measured periodically, along with annual bone age
x-rays. Diets of older children and adults contain more than enough
sodium, obviating the need for supplemental salt. Statural growth
and weight gain are also measured regularly since overtreatment
or undertreatment may be associated with inappropriate growth.
The preferred treatment in children and adults is hydrocortisone,
the least potent glucocorticoid6. Owing to its short half-life, this
drug is given in two or three daily doses. Currently being studied
are newer long-acting or slowly released (or both) glucocorticoid
preparations that could enhance adherence and more closely mimic
physiologic cortisol secretion by the healthy adrenal cortex11,12. Retrospective systematic reviews and meta-analysis have revealed that
exceeding about 17 mg/m2 per day of hydrocortisone equivalents,
especially during early childhood or adolescence, is associated with
poorer height outcomes13. During major life-threatening stress, surgery, or serious illness, patients with CAH require larger or more
frequent doses (or both) of glucocorticoids and additional fluids.
It is therefore crucial to educate parents of young children, and
re-educate patients at the transition to adult care, about stress dosing. Unfortunately, mortality rates for CAH remain unacceptably
high and are thought to be due largely to failure to appropriately
deliver glucocorticoids during serious illness14. Additionally, many
adults with CAH are lost to follow-up, even in countries where
socialized medical care is a basic benefit for all15.

Quality of life and reproductive health in adults
QOL for patients with CAH has been reported as being suboptimal
to poor16,17. With CAH, as with many chronic illnesses, various factors contribute to these measures. In fact, there has been a dearth
of validated CAH-specific QOL instruments. A major negative factor has been sexual function among women who underwent complex genital reconstruction by older surgical techniques18. Newer
approaches seem to provide better outcomes, but detailed long-term
follow-up studies are lacking. Despite exposure to prenatal androgens, women with CAH most often have female core gender identity and behavior19,20. Transgender individuals have been reported
but are relatively rare21.
Fertility and fecundity are reduced in both men and women with
CAH compared with controls22,23. Women who are more severely
affected are less likely to attempt pregnancy24. Additionally, adequate control of adrenal hormones, particularly follicular phase
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progesterone, is key in both conception and fetal retention24.
Pregnant women with classic CAH must be managed by high-risk
practitioners and receive adjustments to steroid doses and careful
fetal monitoring. Interestingly, female fetuses cannot be easily virilized by transplacental passage of maternal androgens and this is
due to a very efficient placental aromatase enzyme system.

Summary
The issues to be resolved in coming years will be reduction of fetal
and neonatal morbidities and mortality associated with CAH by
improved diagnostic methods as discussed above. Patient education
is key to guarantee continued utilization of medical services and

decreased mortality in later life. Stunted growth may be avoided by
improving available steroid treatment options, thereby improving
adherence. Finally, long-term outcome studies of newer genital surgery techniques will help guide management across the life span.

Abbreviations
CAH, congenital adrenal hyperplasia; QOL, quality of life.
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